menu
    • menu

    Company profile for Seed Therapeutics

    NEW Drugs in Dev: 2
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Seed Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use “molecular glues” to attack protein targets previously believed to be ”undruggable.Unlike proteolysis targeting chimera (PROTAC)-based strategies, Seed Therapeutics focuses on discovering “molecular glues” with properties that have the potential to overcome the significant challenges facing any drug candid...
    Seed Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use “molecular glues” to attack protein targets previously believed to be ”undruggable.Unlike proteolysis targeting chimera (PROTAC)-based strategies, Seed Therapeutics focuses on discovering “molecular glues” with properties that have the potential to overcome the significant challenges facing any drug candidate advancing through the different stages of drug development, leading to drug approval. Seed Therapeutics is pioneering the science of improving human health.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Seed TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    28 Liberty Street, 39th Floor New York, NY 10005
    Telephone
    Telephone
    +1 (646) 859-2751
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.seedtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SEED's ST-01156 RBM39 Degrader Shows Early Promise at ASCO 2026
    SEED's ST-01156 RBM39 Degrader Shows Early Promise at ASCO 2026

    02 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/02/3304985/0/en/seed-therapeutics-highlights-clinical-advancement-and-broad-oncology-potential-of-st-01156-an-rbm39-molecular-glue-degrader-in-first-in-human-in-phase-1-studies-at-asco-2026.html

    GLOBENEWSWIRE
    02 Jun 2026
    Share Share
    SEED Therapeutics to Present ST-01156 RBM39 Degrader at ASCO 2026
    SEED Therapeutics to Present ST-01156 RBM39 Degrader at ASCO 2026

    18 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/18/3296482/0/en/seed-therapeutics-to-present-phase-1-trial-design-for-st-01156-a-first-in-human-oral-rbm39-molecular-glue-degrader-at-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    18 May 2026
    Share Share
    SEED Therapeutics Reports Tumor Eradication With RBM39 Degrader
    SEED Therapeutics Reports Tumor Eradication With RBM39 Degrader

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3278824/0/en/seed-therapeutics-reports-tumor-eradication-in-a-neuroblastoma-in-vivo-model-with-clinical-stage-rbm39-molecular-glue-degrader-st-01156.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    SEED Therapeutics Presents Poster At AACR Annual Meeting 2026
    SEED Therapeutics Presents Poster At AACR Annual Meeting 2026

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264522/0/en/SEED-Therapeutics-Announces-Poster-Presentation-at-AACR-Annual-Meeting-2026.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    SEED Therapeutics Doses 1st Patient in Phase 1 Trial of ST-01156
    SEED Therapeutics Doses 1st Patient in Phase 1 Trial of ST-01156

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216206/0/en/SEED-Therapeutics-Doses-First-Patient-in-Phase-1-Trial-of-ST-01156-a-Molecular-Glue-Degrader-Targeting-RBM39.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    SEED Therapeutics Gets IND Clearance From China's NMPA
    SEED Therapeutics Gets IND Clearance From China's NMPA

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186079/0/en/SEED-Therapeutics-Receives-IND-Clearance-from-China-s-NMPA-for-ST-01156.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search